TORONTO, Sept. 15,
2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the
"Company") (TSX: HLS), a pharmaceutical company focused on central
nervous system and cardiovascular markets, announces that it will
be participating in Renmark Financial Communications Inc.'s live
Virtual Non-Deal Roadshow Series on September 22, 2022 at 12:00 PM EDT (11:00 AM
CDT), to discuss its latest investor presentation. For this
event, Renmark is focused on attracting participants in the U.S.
Midwest region. Other interested parties are welcome to attend as
well.
The event will feature Gilbert
Godin, Chief Executive Officer, and Tim Hendrickson, Chief Financial Officer. The
Company's presentation will be followed by a live Q&A.
Investors interested in participating in this event will need to
register using the link below. As a reminder, registration for the
live event may be limited, but access to the replay after the event
will be on the Company's Investor website.
REGISTER HERE:
https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-tsx-hls-2022-09-22-110000
To ensure smooth connectivity, please access this link using the
latest version of Google Chrome.
ABOUT HLS THERAPEUTICS
INC.
Formed in 2015, HLS is a pharmaceutical company focused on the
acquisition and commercialization of late-stage development,
commercial stage promoted and established branded pharmaceutical
products in the North American markets. HLS's focus is on products
targeting the central nervous system and cardiovascular therapeutic
areas. HLS's management team is composed of seasoned pharmaceutical
executives with a strong track record of success in these
therapeutic areas and at managing products in each of these
lifecycle stages. For more information, please visit:
www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.